Y Ko1,2, G Lee1,2, B Kim1,2, M Park1,2, Y Jang1,2,3, W Lim4,5,6. 1. Department of Orthopaedic Surgery, Chosun University Hospital, Gwangju, 61453, South Korea. 2. Laboratory of Orthopaedic Research, Chosun University Hospital, Gwangju, 61453, South Korea. 3. Department of Premedical Program, School of Medicine, Chosun University, Gwangju, 61452, South Korea. 4. Department of Orthopaedic Surgery, Chosun University Hospital, Gwangju, 61453, South Korea. wonbong@chosun.ac.kr. 5. Laboratory of Orthopaedic Research, Chosun University Hospital, Gwangju, 61453, South Korea. wonbong@chosun.ac.kr. 6. Department of Premedical Program, School of Medicine, Chosun University, Gwangju, 61452, South Korea. wonbong@chosun.ac.kr.
Abstract
Here, we proposed the use of mutated RANKL as an immunogen for active immunization and to induce anti-cytokine antibodies for osteoporosis treatment. INTRODUCTION: Osteoclasts are responsible for bone resorption in bone-related disorders. Anti-cytokine therapeutic antibodies such as denosumab are effective for the treatment of osteoporosis. However, problems with antibody manufacturing and the immunogenicity caused by multiple antibody doses have led to the use of auto-cytokines as immunogens to induce anti-cytokine antibodies. METHODS: RANKL was point-mutated based on the crystal structure of the complex of RANKL and its receptor RANK. RESULTS: As a proof of concept, immunization with RANKL produced high levels of specific antibodies and blocked osteoclast development in vitro and inhibited osteoporosis in RANKL-treated or ovariectomized mouse models. CONCLUSIONS: The results demonstrate the successful use of mutated RANKL as an immunogen for the induction of anti-RANKL immune response. This strategy is useful in general anti-cytokine immunotherapy to avoid toxic side effects of osteoporosis treatment.
Here, we proposed the use of mutated RANKL as an immunogen for active immunization and to induce anti-cytokine antibodies for osteoporosis treatment. INTRODUCTION: Osteoclasts are responsible for bone resorption in bone-related disorders. Anti-cytokine therapeutic antibodies such as denosumab are effective for the treatment of osteoporosis. However, problems with antibody manufacturing and the immunogenicity caused by multiple antibody doses have led to the use of auto-cytokines as immunogens to induce anti-cytokine antibodies. METHODS:RANKL was point-mutated based on the crystal structure of the complex of RANKL and its receptor RANK. RESULTS: As a proof of concept, immunization with RANKL produced high levels of specific antibodies and blocked osteoclast development in vitro and inhibited osteoporosis in RANKL-treated or ovariectomized mouse models. CONCLUSIONS: The results demonstrate the successful use of mutated RANKL as an immunogen for the induction of anti-RANKL immune response. This strategy is useful in general anti-cytokine immunotherapy to avoid toxic side effects of osteoporosis treatment.
Authors: V Everts; J M Delaissé; W Korper; D C Jansen; W Tigchelaar-Gutter; P Saftig; W Beertsen Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: Gunther Spohn; Katrin Schwarz; Patrik Maurer; Harald Illges; Narendiran Rajasekaran; Yongwon Choi; Gary T Jennings; Martin F Bachmann Journal: J Immunol Date: 2005-11-01 Impact factor: 5.422
Authors: T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey Journal: J Cell Biol Date: 1999-05-03 Impact factor: 10.539
Authors: Nadia Lo Iacono; Harry C Blair; Pietro L Poliani; Veronica Marrella; Francesca Ficara; Barbara Cassani; Fabio Facchetti; Elena Fontana; Matteo M Guerrini; Elisabetta Traggiai; Francesca Schena; Marianna Paulis; Stefano Mantero; Antonio Inforzato; Serenella Valaperta; Alessandra Pangrazio; Laura Crisafulli; Virginia Maina; Paul Kostenuik; Paolo Vezzoni; Anna Villa; Cristina Sobacchi Journal: J Bone Miner Res Date: 2012-12 Impact factor: 6.741